Influenza virus encoding a truncated NS1 protein and a SARS-CoV receptor binding domain
The present invention refers to a recombinant influenza vims encoding a fusion protein comprising a truncated NS1 protein and a SARS-CoV receptor binding domain, specifically a SARS-CoV-2 RBD, and its use for prophylactic treatment, a pharmaceutical preparation comprising said virus for use in prime boost vaccination and a two-component vaccine for prime boost vaccination.
1 . A recombinant influenza virus comprising a modified NS segment, encoding:
a) a fusion protein comprising from N to C-terminus:
a truncated NS1 protein consisting of 10 to 20 amino acids of the N-terminus of the respective wild type NS1 protein,
optionally a linker sequence,
optionally a 2A self-cleaving peptide, specifically a P2A sequence,
a signal peptide,
a SARS-COV receptor binding domain (RBD) comprising up to 40, up to 30, or up to 27 amino acids of the C-terminal of the SARS-COV S1 subunit, and
b) an NS2 protein.
2 . The recombinant influenza virus of claim 1 , wherein said virus is a human influenza B virus.
3 . The recombinant influenza virus of claim 1 , wherein the truncated NS1 protein comprises up to 16 of its N-terminal 10 to 18 amino acids.
4 . The recombinant influenza virus of claim 1 , comprising SEQ ID Nos: 1-6 or SEQ ID Nos: 54-57.
5 . The recombinant influenza virus of claim 1 , wherein the linker is a GS linker having a length of 2 to 10 amino acids.
6 . The recombinant influenza virus of claim 1 , comprising modifications of the NA and/or HA proteins.
7 . The recombinant influenza virus of claim 1 , wherein the RBD is fused to a transmembrane domain.
8 . The recombinant influenza virus of claim 1 , wherein the virus is combined with a physiologically acceptable excipient to form a pharmaceutical preparation.
9 . The recombinant influenza virus claim 8 , wherein the virus is present in the pharmaceutical preparation in an effective amount.
10 . A method of providing prophylactic immunization against a disease condition which is caused by or associated with an infection by a coronavirus and/or influenza virus, comprising the step of administering an effective amount of the recombinant influenza virus of claim 1 , wherein the immunity induced is effective in preventing infection of susceptible cells by the virus, thereby treating the disease condition.
11 . The recombinant influenza virus of claim 8 , wherein said pharmaceutical preparation is formulated for local administration to the upper and lower respiratory tract or for nasal, pulmonary, intraoral, ocular, or dermal administration, or for systemic parenteral administration.
12 . The recombinant influenza virus of claim 8 , wherein said pharmaceutical preparation is in the form of a spray, a powder, a gel, an ointment, a cream, a foam, or a liquid solution, a lotion, a patch, a gargle solution, an aerosolized powder, an aerosolized liquid formulation, granules, or capsules.
13 . The recombinant influenza virus of claim 1 , wherein the coronavirus is a B-coronavirus selected from the group consisting of SARS-COV-2, MERS-COV, SARS-COV-1, HCoV-OC43, and HCoV-HKU1, or mutants thereof.
14 . An isolated nucleic acid sequence expressing the recombinant influenza virus of claim 1 .
15 . The nucleic acid sequence of claim 14 , comprising one or more artificial splice sites within the gene encoding the truncated NS1 protein.
16 . A method of vaccinating a subject with a two-component vaccine comprising the recombinant influenza virus of claim 1 with native hemagglutinin (HA) from Victoria or Yamagata lineages, comprising:
administering a priming composition comprising one, two or three recombinant influenza virus strains of claim 1 , and
administering a boosting composition comprising one, two or three recombinant influenza virus strains of claim 1 , wherein the influenza virus strains of the boosting composition comprise HA which antigenically differ from the HA of the influenza virus strains of the priming composition.
17 . The method of claim 16 , wherein the HA head of the influenza virus strains of the priming composition is antigenically different from the HA head of the influenza virus strains of the boosting composition.
18 . The method of claim 16 , wherein the boosting composition is administered 2 to 8 weeks after the priming composition.
19 . The method of claim 16 , wherein the boosting composition is administered about 3 weeks after the priming composition.
20 . The method of claim 16 , wherein the recombinant influenza virus of the priming composition comprises a native HA with a B/Victoria derived HA, and the recombinant influenza virus of the boosting composition comprises a native HA with a B/Yamagata lineage HA, or wherein the recombinant influenza virus of the priming composition comprises a native HA with a B/Victoria lineage derived HA, and the recombinant influenza virus of the boosting composition comprises a native HA with a B/Yamagata lineage derived HA.